C. Ma

Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.

P. Shaw, A. Yong, E. Blyth, 2017, Blood advances.

Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-speci fi c T cells

P. Shaw, A. Yong, E. Blyth, 2017 .

Herpes simplex virus type 1 (HSV-1) specific T-cell generation from HLA-A1- and HLA-A2-positive donors for adoptive immunotherapy.

E. Blyth, D. Gottlieb, K. Micklethwaite, 2017, Cytotherapy.

Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R‐ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation

I. Kerridge, M. Greenwood, W. Xia, 2014, Journal of clinical apheresis.

Poor prognosis in patients with steroid refractory acute graft versus host disease treated with etanercept: a multi-centre analysis

J. Sierra, R. Martino, D. Ma, 2018, Bone Marrow Transplantation.

In vitro generation of influenza-specific polyfunctional CD4+ T cells suitable for adoptive immunotherapy.

E. Blyth, D. Gottlieb, L. Clancy, 2012, Cytotherapy.

Addition of varicella zoster virus-specific T cells to cytomegalovirus, Epstein-Barr virus and adenovirus tri-specific T cells as adoptive immunotherapy in patients undergoing allogeneic hematopoietic stem cell transplantation.

E. Blyth, D. Gottlieb, K. Micklethwaite, 2015, Cytotherapy.

Prophylactic antigen‐specific T‐cells targeting seven viral and fungal pathogens after allogeneic haemopoietic stem cell transplant

F. Luciani, B. Gloss, H. McGuire, 2021, Clinical & translational immunology.

Donor-derived CMV-specific T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation.

K. Byth, P. Shaw, E. Blyth, 2013, Blood.

TRANSPLANTATION Donor-derived CMV-speci fi c T cells reduce the requirement for CMV-directed pharmacotherapy after allogeneic stem cell transplantation

K. Byth, Peter Shaw, E. Blyth, 2013 .

Cytomegalovirus-specific cytotoxic T lymphocytes can be efficiently expanded from granulocyte colony-stimulating factor-mobilized hemopoietic progenitor cell products ex vivo and safely transferred to stem cell transplantation recipients to facilitate immune reconstitution.

P. Shaw, E. Blyth, D. Gottlieb, 2013, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Adjuvant Peptide Pulsed Dendritic Cell Vaccination in Addition to T Cell Adoptive Immunotherapy for Cytomegalovirus Infection in Allogeneic Hematopoietic Stem Cell Transplantation Recipients.

E. Blyth, D. Gottlieb, K. Micklethwaite, 2018, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.